Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory
View Patent ↗The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
1. A method of inhibiting Aβ production in a cell comprising:
exposing cells to a peptide comprising an N-terminal domain of Presenilin-1, thereby inhibiting the binding of the N-terminal extracellular domain of βAPP with the N-terminal extracellular region of PS-1 and PS-2, or PS-1 or PS-2 and thereby inhibiting Aβ.
2. The method of claim 1 , wherein the peptide is a soluble N-terminal domain of PS-1.
3. The method of claim 1 , wherein the peptide is formulated with a pharmaceutically acceptable carrier.
4. A method of inhibiting Aβ production in a cell comprising contacting a cell with a peptide comprising an N-terminal soluble domain of Presenilin-1, wherein the peptide inhibits the interaction of βAPP with Presenilin-1, and thereby inhibiting Aβ production.
5. The method of claim 4 , wherein the peptide inhibits a G-protein coupled receptor activity of presenilin-1.
6. The method of claim 4 , wherein the peptide is formulated with a pharmaceutically acceptable carrier.